Cystatin C

Structure and Physiology

• Small size: passes freely through the glomerular filtration barrier
• High isoelectric point (pI 9.2): positively charged at physiologic pH, which facilitates glomerular filtration more readily than some other markers
• Half-life: ~1.5 hours (shorter than creatinine's ~4 hours)
• Volume of distribution: matches extracellular fluid (unlike creatinine, which distributes throughout total body water)

Role as a GFR Marker

• Freely filtered at the glomerulus
• Not secreted by tubules
• Completely reabsorbed (not measurable in urine clearance)

Advantages over Creatinine

Factors That Alter Cystatin C Independent of GFR

• Glucocorticoids - reduce production, so GFR may be overestimated in transplant patients on steroids
• Thyroid dysfunction - hypothyroidism raises levels; hyperthyroidism lowers them
• Obesity and high BMI
• Diabetes mellitus
• Smoking
• High C-reactive protein / inflammation (via IL-10 pathway - interleukin-10 inhibits cystatin C production)
• Certain malignancies
• Age and sex - levels are higher in males, increase with age, and are notably elevated in >50% of those over age 80

GFR Estimation Equations

• CKD-EPI creatinine (2009/2021)
• CKD-EPI cystatin C (2012)
• CKD-EPI creatinine-cystatin C combined (2012) - this combined equation outperforms either alone; it achieves GFR within 20% of measured GFR in a significantly higher proportion of patients and provides better classification of CKD stages

GFR = 84.69 × cystatin C (mg/L)^-1.680 × 1.384 (if child < 14 years)

Urinary Cystatin C - Tubular Injury Marker

Clinical Applications

Chronic Kidney Disease (CKD)

• More accurate CKD staging than creatinine alone
• The combined creatinine + cystatin C equation reduces reclassification errors and improves risk stratification for ESRD and mortality
• Particularly useful in: elderly patients, HIV-infected individuals, low muscle mass states, and situations where creatinine is unreliable

Acute Kidney Injury (AKI)

• Serum cystatin C rises 24-48 hours before creatinine in some ICU studies (AUC ~0.97 for predicting AKI)
• Useful for detecting contrast-induced nephropathy earlier than creatinine

Cardiovascular Risk

• Cardiovascular mortality (HR ~2.27)
• Myocardial infarction (HR ~1.48)
• Stroke (HR ~1.47)

Laboratory Measurement

• Method: Particle-enhanced turbidimetric immunoassay (PETIA) or nephelometric immunoassay (PENIA) - both run on automated analyzers
• Reference range (adults 23-50 years): 0.6-1.1 mg/L (using ERM-DA471/IFCC standardized assays)
• Precision: Between-day CV of 2-4%; within-subject biological variation ~4%
• Standardization: The international reference material ERM-DA471/IFCC was developed to harmonize assays across manufacturers - results must be traceable to this standard for direct comparability
• Cost: Reagents are more expensive than creatinine assays, though automated platforms have reduced costs (approx. $4/test)

Summary Box (from Brenner & Rector's)

1. Serum cystatin C performs on par with or better than serum creatinine for identifying CKD
2. It specifically outperforms creatinine in older adults and HIV-infected individuals
3. It outperforms creatinine for detecting those at risk for cardiovascular morbidity and mortality
4. Serum cystatin C should be incorporated into routine nephrologist assessment of CKD

Recent Evidence Note

Thyroid Dysfunction and Cystatin C

The Core Mechanism

Effect of Each Thyroid State

Hyperthyroidism

• Thyroid hormone excess increases cystatin C production
• Serum cystatin C rises above what would be expected for the actual GFR
• This means cystatin C-based eGFR will underestimate true GFR
• The patient appears to have worse kidney function than they actually do

Hypothyroidism

• Thyroid hormone deficiency decreases cystatin C production
• Serum cystatin C falls below what would be expected for the actual GFR
• This means cystatin C-based eGFR will overestimate true GFR
• The patient appears to have better kidney function than they actually do

Subclinical Thyroid Dysfunction

• Even subclinical changes in thyroid status have been shown to affect cystatin C levels, though the magnitude is smaller than in overt disease

Quantitative Evidence (Meta-Analysis)

Clinical Implications

1. GFR Estimation Errors in Thyroid Disease

• In hyperthyroid patients: serum cystatin C is elevated not because of kidney disease but due to increased production - cystatin C-based eGFR falsely suggests CKD
• In hypothyroid patients: serum cystatin C is lowered - cystatin C-based eGFR falsely suggests better kidney function than is real
• Creatinine-based eGFR is also affected in thyroid disease (hypothyroidism reduces muscle creatinine turnover, lowering creatinine), but through a different mechanism

2. Transplant and Corticosteroid Context

3. When to Be Cautious

• Known hypo- or hyperthyroidism
• Patients on thyroid hormone replacement (T4/T3) - especially if recently dose-adjusted
• Patients on antithyroid drugs (carbimazole, propylthiouracil) - treatment will lower cystatin C as thyroid function normalizes
• Sick euthyroid syndrome (low T3 in critical illness) - may suppress cystatin C

4. Recommended Approach

• Use measured GFR (iohexol, inulin clearance) if a precise value is needed
• Consider the combined creatinine-cystatin C equation (eGFRcr-cys), which partially mitigates isolated non-GFR confounders
• Interpret cystatin C results in the context of thyroid function tests (TSH, fT4)
• Re-check cystatin C after thyroid disease has been treated and euthyroid state restored

Summary

Mechanism: How Thyroid Hormones Regulate Cystatin C

Pathway 1: Direct T3 Action (Transcriptional Upregulation)

Step-by-step:

1. T4 → T3 conversion at the tissue level by type 2 deiodinase (D2) produces the active form, triiodothyronine (T3)
2. T3 crosses the cell membrane and enters the nucleus (via transporters such as MCT8 in some tissues)
3. T3 binds thyroid hormone receptors (TRα or TRβ) - nuclear receptors that exist predominantly as heterodimers with RXR (retinoid X receptor)
4. The T3-TR-RXR complex binds to Thyroid Response Elements (TREs) in the promoter/enhancer regions of target genes
5. T3 binding displaces co-repressors (NCoR, SMRT) and recruits co-activators - this switches the gene from repressed to actively transcribed
6. CST3 mRNA is upregulated → more cystatin C protein is synthesized and secreted by nucleated cells

Key evidence:

• Schmid et al. showed that T3 directly increases cystatin C production in Hep G2 hepatoblastoma cells (kept in thyroid hormone-stripped medium) by approximately ~30%, confirmed by both RT-PCR (mRNA) and nephelometric immunoassay (secreted protein)
• This confirms the effect is at the level of production, not clearance - it is the synthesis rate that changes, not how fast the kidney removes cystatin C

Pathway 2: Indirect - via TGF-β1

1. T3 also stimulates production of TGF-β1 (transforming growth factor-beta 1) - serum TGF-β1 is elevated in hyperthyroidism and reduced in hypothyroidism
2. TGF-β1 independently stimulates cystatin C secretion from vascular smooth muscle cells and upregulates CST3 transcript in murine embryo cells and 3T3-L1 fibroblasts
3. The result: TGF-β1 acts as a second messenger, amplifying the direct T3 effect on cystatin C output

Key evidence (Kotajima et al.):

• In Graves' disease patients: serum TGF-β1 and cystatin C were both significantly elevated
• Positive correlations were found between:
  • Thyroid hormones ↔ cystatin C
  • Thyroid hormones ↔ TGF-β1
  • TGF-β1 ↔ cystatin C
• After treatment of hyperthyroidism: both TGF-β1 and cystatin C fell together
• In Hep G2 cell culture: both T3 and TGF-β1 independently increased cystatin C mRNA and secreted protein

Why Production, Not Clearance?

• In hyperthyroid patients, cystatin C remains elevated despite increased GFR (hyperthyroidism actually raises GFR modestly due to increased cardiac output and renal blood flow)
• In hypothyroid patients, cystatin C remains low despite reduced GFR
• These paradoxical findings are only explained by production-rate changes overriding the GFR signal

Integrated Diagram

Hyperthyroidism (↑T3/T4)
        │
        ├──► Direct: T3 → TR/RXR heterodimer binds TRE in CST3 promoter
        │           → ↑ CST3 mRNA → ↑ Cystatin C secretion (~30% increase)
        │
        └──► Indirect: T3 → ↑ TGF-β1 production
                          → TGF-β1 binds own receptors on nucleated cells
                          → ↑ CST3 mRNA (independent of T3)
                          → Further ↑ Cystatin C secretion

Net result: Serum Cystatin C ↑ (falsely suggesting ↓ GFR)

Hypothyroidism (↓T3/T4) → Both pathways attenuated → ↓ Cystatin C
                                                       (falsely suggesting ↑ GFR)

Bottom Line

How Thyroid Hormones Affect Cystatin C (Simplified)

First, understand the basics

• More cystatin C in blood = kidneys filtering less = lower GFR
• Less cystatin C in blood = kidneys filtering more = higher GFR

Think of thyroid hormones as a "volume dial" for cell activity

• Hyperthyroid = dial turned up → cells work faster → they produce more cystatin C
• Hypothyroid = dial turned down → cells work slower → they produce less cystatin C

The two ways T3 increases cystatin C

Way 1: Direct (T3 talks directly to the gene)

1. T3 enters the cell nucleus
2. It latches onto a receptor (like a key in a lock)
3. That receptor-T3 complex sits on the cystatin C gene and says "make more of this protein"
4. The cell produces ~30% more cystatin C mRNA, and thus more cystatin C protein

Way 2: Indirect (T3 uses a middleman - TGF-β1)

1. T3 also tells cells to produce more of another molecule called TGF-β1
2. TGF-β1 then goes to other cells and tells them to also make more cystatin C
3. It is like T3 sending a memo to a manager (TGF-β1), who then passes the message down to all the workers

The paradox this creates

• The heart pumps faster → kidneys actually get more blood flow → GFR goes up
• But despite better kidney function, cystatin C is high because cells are overproducing it
• Lab result: cystatin C says "kidneys are failing" - but they are actually working fine or better

• Metabolism slows → kidney blood flow drops → GFR goes down
• But cystatin C is low because cells are underproducing it
• Lab result: cystatin C says "kidneys are fine" - but they are actually a bit sluggish

One-line summary per state

Practical takeaway